ENFIELD, England, August 28 /PRNewswire/ --

Noble Gift Packaging, a leading innovator of custom-designed gift packaging, today unveiled a new 32-page, color catalogue that makes it easy for packagers and retailers to go green and look good doing it. The catalogue introduces the new ZeroTree(TM) collection of stylish bags and other eco-friendly packaging products, which are made from a variety of environmentally responsible materials and techniques that reduce reliance on trees and encourage recycling and reuse.

It has long been a dream of developmental biologists to easily reprogram one type of fully formed adult cell into another type of adult cell without using stem cells. By reprogramming cells, you might be able to treat many diseases where certain cells are lost or damaged, like diabetes or Parkinson's. Now, a truly exciting new study from the Harvard Stem Cell Institute (HSCI) is making that dream become reality. In a brand new study published in the journal Nature, Harvard Stem Cell Institute (HSCI) co-director Doug Melton and post doctoral fellow Qiao "Joe" Zhou report having taken one type of fully differentiated cell, called an exocrine cell (it makes gut enzymes and is involved in digesting food), and converting it into an entirely different cell using certain kinds of genes called transcription factors (a gene that encodes proteins that turn 'on' or 'off' other sets of genes). In many ways, their different kind cell is a much more useful kind of cell. The amazing thing? They didn't use stem cells.

LITTLETON, Colorado, August 28 /PRNewswire/ --

CPI Card Group, a portfolio company of Tricor Pacific Capital, Inc., a private equity firm with offices in Vancouver, B.C., and Lake Forest (Chicago), Illinois, has acquired PCC, a leading plastic card manufacturing, personalization, and fulfillment company. PCC is a major supplier to the Western European market and is located in the United Kingdom. PCC is led by a strong management team that will continue with the business as employees of CPI.

It sounds like a sales job from a 12 year old; "Actually, Dad, this is not just another video game. Its a virtual, scenario-based microcosm of real world experiences that will enhance my decision-making abilities and my cognitive perceptions of the challenges of the sport's environment." 

You respond with, "So, how much is Madden 09?"

  With over 5 million copies of Madden 08 sold, the release of the latest version two weeks ago is rocketing up the charts.  Days and late nights are being spent all over the world creating rosters, customizing plays and playing entire seasons, all for pure entertainment purposes.

  Can all of those hours spent with controller in hands actually be beneficial to young athletes?  Shouldn't they be outside in the fresh air and sunshine playing real sports?  Well, yes, to both questions.

On August 26th, a group of LHC critics filed a suit against CERN in the European Court of Human Rights, in Strasbourg . The authors of the suit are physicists, professors and students largely from Germany and Austria, who feel that the operation of the $10 billion Large Hadron Collider near Geneva, poses grave risks for the safety and well-being of the 27 member states of the European Union and their citizens. The Rule of Law, the suit states, is also threatened. The legal arguments that define the legitimacy of the suit have been crafted in German by a Professor of International Law, Adrian Hollaender.

MOUNTAIN VIEW, California and VALENCIA, Spain, August 28 /PRNewswire/ --

SolFocus, Inc. today announced that it will be sponsoring, presenting and exhibiting at the 23rd European Photovoltaic Solar Energy Conference (PVSEC) in Valencia, Spain on September 1st-4th, 2008. The PVSEC is one of the most important international conferences in the photovoltaic field, hosting more than 3,000 scientists, industry representatives and politicians from 83 countries, as well as 12,000 visitors. As a sponsor of the event, SolFocus will co-host the Welcome Reception on September 1st.

STAINES, England, August 28 /PRNewswire/ --

- Not for distribution in the United Kingdom

- Research Adds to Already Demonstrated Efficacy in Adult Population

Parents and paediatricians are today welcoming the results of new research that adds additional support for an effective and well tolerated treatment for children with invasive candidiasis. The research, published today in the September edition of The Pediatric Infectious Disease Journal(i), demonstrates that Mycamine(R) (micafungin) delivers high success rates(*) (i) in the treatment of premature infants, babies up to four weeks old and children. The study also shows significantly less adverse events (i) leading to treatment discontinuation with Mycamine(R) compared to liposomal amphotericin B therapy.

LEUVEN, Belgium, August 28 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.

LEUVEN, Belgium, August 28 /PRNewswire/ --

- Professor Desire Collen Will Remain as Chairman of the Board and Scientific Advisor

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces today that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer on September 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.

DETROIT, LONDON and MUMBAI, India, August 28 /PRNewswire/ --

- 'INCAT is defining the global landscape,' CEO says

INCAT, a global leader in Engineering Services Outsourcing (ESO) and Product Development IT services, today announced the worldwide release of a new booklet, "Global Delivery - An Essential Guide to Engineering Services Outsourcing." The 50-page guide provides readers a definitive summary of the business of Global Delivery and how to approach it, as well as what - and where - to deploy. It is available in both print and electronic versions.